AVEO stock: buy or sell?

AVEO stock price: $0.59 -1.67% At close on January 24th, 2020

Updated on:
January 24th, 2020

1

AVEO shares slipped -1.67% to $0.59 yesterday. With Friday it's been 5 red days in a row.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF\u002Fc-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.

Should I buy AVEO stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with AVEO Pharmaceuticals stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AVEO will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is AVEO stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we collected 8 ratings published for AVEO stock in the last month.

Is AVEO a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-11HC WainwrightNeutralBuy
2019-9-10Piper Jaffray Companiesn/aOverweight
2019-3-28National Securitiesn/aSell
2019-3-18HC Wainwrightn/aHold
2019-2-4B. RileyBuyNeutral
2019-2-4B. RileyBuyNeutral
2019-2-1HC WainwrightBuyNeutral
2019-2-1HC WainwrightBuyNeutral

AVEO stock analysis

Daily outlook

AVEO shares slipped -1.67% to $0.59 yesterday.

AVEO shares slipped -1.67% to $0.59 yesterday. Since last November when AVEO stock price broke down the SMA200d line, it slid $-0.30 per share (-33.71%). AVEO is retaking the upward trend marking a new rising bottom heading to break out over $0.70.

AVEO stock chart (daily)

Weekly outlook

AVEO shares collapsed -7.81% this week, ending at $0.59. Early January AVEO boosted a dazzling 7.46% in just one week.

Since SMA20w and SMA40w crossed up last week, AVEO price slid a -11.94%. Since early November 2019, when AVEO stock price broke down the 40-weeks moving avarage line, it slid $-0.30 per share (-33.71%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.

AVEO stock chart (weekly)

AVEO stock price history

AVEO IPO was on March 12th, 2010 at $8.25 per share1. Since then, AVEO stock lost a -92.80%, with a yearly average of -10.30%.

1: Adjusted price after possible price splits or reverse-splits.

AVEO stock historical price chart

AVEO stock reached 52-week highs at $1.86, and all-time highs 2011-07-06 with a price of 21.55.

AVEO stock price target is $1.50

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we found 7 price forecasts for AVEO stock:
AVEO stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-11HC WainwrightUpgrades$1.00$1.7575%
2019-9-10Piper Jaffray CompaniesRaises Target$3.00$4.0033.3%
2019-3-18HC WainwrightReiteratesn/a$1.00-
2019-2-4B. RileyReiterates$5.00$1.00-80%
2019-2-4B. RileyDowngrades$5.00$1.00-80%
2019-2-1HC WainwrightReiteratesn/a$1.00-
2019-2-1HC WainwrightDowngradesn/a$1.00-
(in average)$3.50$1.50-57.0%
The price target for AVEO Pharmaceuticals stock is $1.50, moving in a range between $4.00 and $1.00. In average, analysts' outlook on AVEO price forecast is negative, reducing the prediction by a -57.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, AVEO missed the estimates of the analysts and reported a spooky EPS of $-0.03 per share when experts were expecting $-0.06.
AVEO earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.12n/a
2017-Q2-n/a-0.3n/a
2017-Q3-n/a-0.22n/a
2017-Q42018-03-13-0.02-0.08n/a
2018-Q12018-05-08-0.07-0.08n/a
2018-Q22018-08-07-0.06-0.15n/a
2018-Q32018-11-09-0.06-0.05n/a
2018-Q42019-03-14-0.06-0.03n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual sales report draw a spooky correction of -28.63% to $5.41 million dollars. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) skyrocketed a 759.44% to -98.52%.

AVEO annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$1.29 M-$-107.03 M-8296.9%-
2014$18 M1,304.88%$-52.74 M-291.0%-50.73%
2015$19 M4.97%$-15.00 M-78.9%-71.56%
2016$2.52 M-86.78%$-26.89 M-1069.1%79.23%
2017$7.58 M201.35%$-65.03 M-858.0%141.85%
2018$5.41 M-28.63%$-5.33 M-98.5%-91.80%

Quarterly financial results

AVEO posted $1.48 M in revenues for 2018-Q4, a -39.89% decline compared to previous quarter. Reported quarter income marked $21.82 million with a profit margin of 1,471.21%. Profit margin climbed a 2,369.59% compared to previous quarter when profit margin was -898.38%. When comparing revenues to same quarter last year, AVEO Pharmaceuticals sales marked a super good gain and rocketed a 1,708.54%.
AVEO quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$2.53 M-$-8.84 M-349.4%-
2017-Q2$0.35 M-86.13%$-33.29 M-9484.3%276.58%
2017-Q3$4.61 M1,214.53%$-26.40 M-572.1%-20.71%
2017-Q4$0.08 M-98.22%$3.50 M4267.1%-113.26%
2018-Q1$1.03 M1,151.22%$-8.99 M-876.0%-356.87%
2018-Q2$0.43 M-57.80%$4.00 M924.7%-144.55%
2018-Q3$2.47 M469.75%$-22.16 M-898.4%-653.52%
2018-Q4$1.48 M-39.89%$21.82 M1471.2%-198.44%

AVEO ownership

When you are planning to invest in a stock, it's worth to check its ownership structure.

AVEO Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

For a better understanding, the following table shows ownership data compared to other related stocks:

AVEO
Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

AVEO summary

Friday, January 24th, 2020
Open$0.62
Close$0.59
Day range$0.58 - $0.62
Previous close$0.60
Session gain-1.67%
Average true range$0.03
50d mov avg$0.66
100d mov avg$0.75
200d mov avg$0.75
Daily patternlb02a
Weekly pattern lt11c

AVEO performance

To better understand AVEO performance you must compare its gains with other related stocks in same sector or industry. For AVEO Pharmaceuticals, the benchmark is made against .
Stock3m6m12m
AVEOAVEO Pharmaceutic...-35.87%-7.81%-67.40%

AVEO competitors

Unfortunately, we could not find any public company that could be defined as AVEO Pharmaceuticals competitor. This doesn't mean AVEO Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.